Significant Contribution of Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography (FDG PET/CT) in a Case of Acute Lymphoblastic Leukemia Presenting with Fever of Unknown Origin

Fluorodesoxyglucose Positron Emission Tomography (PET/CT) has never been compared to Chest-Abdomen-Pelvis CT (CAPCT) in patients with a fever of unknown origin (FUO), inflammation of unknown origin (IUO) and episodic fever of unknown origin (EFUO) through a prospective and multicentre study. In this study, we investigated the diagnostic value of PET/CT compared to CAPCT in these patients. The trial was performed between 1 May 2008 through 28 February 2013 with 7 French University Hospital centres. Patients who fulfilled the FUO, IUO or EFUO criteria were included. Diagnostic orientation (DO), diagnostic contribution (DC) and time for diagnosis of both imaging resources were evaluated. One hundred and three patients were included with 35 FUO, 35 IUO and 33 EFUO patients. PET/CT showed both a higher DO (28.2% vs. 7.8%, p < 0.001) and DC (19.4% vs. 5.8%, p < 0.001) than CAPCT and reduced the time for diagnosis in patients (3.8 vs. 17.6 months, p = 0.02). Arthralgia (OR 4.90, p = 0.0012), DO of PET/CT (OR 4.09, p = 0.016), CRP > 30 mg/L (OR 3.70, p = 0.033), and chills (OR 3.06, p = 0.0248) were associated with the achievement of a diagnosis (Se: 89.1%, Sp: 56.8%). PET/CT both orients and contributes to diagnoses at a higher rate than CAPCT, especially in patients with FUO and IUO, and reduces the time for diagnosis.

Download Full-text

Is fludeoxyglucose-fluorodeoxyglucose-positron emission tomography/computed tomography (18F-FDG-PET/CT) really useless in staging pulmonary carcinoid tumors and in discriminating histological subtypes? Controversial points and future perspectives

Annals of Thoracic Medicine ◽

10.4103/1817-1737.157292 ◽

2015 ◽

Vol 10 (3) ◽

pp. 217 ◽

Cited By ~ 2

Author(s):

Filippo Lococo ◽

Alessandro Stefani ◽

Giorgio Treglia

Keyword(s):

Emission Tomography ◽

Fluorodeoxyglucose Positron Emission Tomography ◽

Future Perspectives ◽

Histological Subtypes ◽

Pulmonary Carcinoid ◽

Positron Emission ◽

Pet Ct ◽

18F Fdg ◽

Fdg Pet Ct ◽

Fluorodeoxyglucose Positron Emission

Download Full-text

AB0595 THE USEFULNESS OF 18F-FLUORODEOXYGLUCOSE POSITRON EMISSION TOMOGRAPHY CT (18F-FDG PET/CT) AS AN IMAGING BIOMARKER IN TAKAYASU ARTERITIS TREATED WITH TOCILIZUMAB

10.1136/annrheumdis-2019-eular.4429 ◽

2019 ◽

Author(s):

Mikiya Kato ◽

Hanae Okuda ◽

Tomohiro Kameda ◽

Taichi Miyagi ◽

Risa Wakiya ◽

...

Keyword(s):

Positron Emission Tomography ◽

Takayasu Arteritis ◽

Emission Tomography ◽

Imaging Biomarker ◽

Fluorodeoxyglucose Positron Emission Tomography ◽

Positron Emission ◽

Pet Ct ◽

18F Fdg ◽

Fdg Pet Ct ◽

Fluorodeoxyglucose Positron Emission

Download Full-text

Fluorodeoxyglucose Positron Emission Tomography–Computed Tomography: A Novel Approach for the Diagnosis of Cholecystitis for Equivocal Diagnoses after Ultrasound Imaging

The American Surgeon ◽

10.1177/000313481207801022 ◽

2012 ◽

Vol 78 (10) ◽

pp. 1109-1113

Author(s):

Yosef Nasseri ◽

Ariel J. Ourian ◽

Alan Waxman ◽

Alessandro D'Angolo ◽

Louise E. Thomson ◽

...

Keyword(s):

Computed Tomography ◽

Positron Emission Tomography ◽

Fdg Pet ◽

Emission Tomography ◽

Fluorodeoxyglucose Positron Emission Tomography ◽

Hida Scan ◽

Positron Emission ◽

Pet Ct ◽

Fdg Pet Ct ◽

Fluorodeoxyglucose Positron Emission

Although hepatobiliary iminodiacetic acid (HIDA) scan is often used when the diagnosis of cholecystitis remains questionable after ultrasound, it carries a high false-positive rate and has other limitations. Fluorodeoxyglucose positron emission tomography–computed tomography (18FDG PET-CT) has recently gained enthusiasm for its ability to detect infection and inflammation. In this study, we evaluate the accuracy of 18FDG PET-CT in diagnosing cholecystitis. Nineteen patients with suspected cholecystitis (Group S) underwent PET-CT and 10 had positive PET-CT findings. Of these 10, nine underwent cholecystectomies, and pathology confirmed cholecystitis in all nine. One patient was managed nonoperatively as a result of multiple comorbidities. Of the nine patients with negative PET-CT, six were managed nonoperatively, safely discharged, and had no readmissions at 3-month follow-up. The other three patients with negative PET-CT underwent cholecystectomies, and two showed no cholecystitis on pathology. The third had mild to moderate cholecystitis with focal mucosal erosion/ulceration without gallbladder wall thickening on pathology. 18FDG PET-CT detected gallbladder inflammation in all but one patient with pathology-proven cholecystitis with a sensitivity and specificity of 0.90 and 1.00, respectively. 18FDG-PET-CT appears to be a promising, rapid, direct, and accurate test in diagnosing cholecystitis and could replace HIDA scan in cases that remain equivocal after ultrasound.

Download Full-text

18F-fluorodeoxyglucose positron emission tomography is useful for the diagnosis of intraocular sarcoidosis in patients with a normal CT scan

British Journal of Ophthalmology ◽

10.1136/bjophthalmol-2018-313133 ◽

2019 ◽

Vol 103 (11) ◽

pp. 1650-1655 ◽

Cited By ~ 2

Author(s):

Pierre Chauvelot ◽

Andrea Skanjeti ◽

Yvan Jamilloux ◽

Audrey de Parisot ◽

Christiane Broussolle ◽

...

Keyword(s):

Positron Emission Tomography ◽

Ct Scan ◽

Predictive Factors ◽

Fdg Pet ◽

Emission Tomography ◽

Fluorodeoxyglucose Positron Emission Tomography ◽

Positron Emission ◽

Pet Ct ◽

Fdg Pet Ct ◽

Fluorodeoxyglucose Positron Emission

AimTo assess the usefulness of 18F-fluorodeoxyglucose positron emission tomography (18F-FDG PET/CT) and the predictive factors for the diagnosis of sarcoidosis in patients with uveitis who have normal thoracic tomography.MethodsWe retrospectively reviewed 67 consecutive patients with uveitis of unknown aetiology or a suspected sarcoidosis. All patients with normal thoracic tomography underwent an 18F-FDG PET/CT, which was blindly reinterpreted. We then assessed the proportion of positive 18F-FDG PET/CT and the impact on the final aetiology, using Abad’s criteria for the diagnosis of intraocular sarcoidosis.Results19 of the 67 patients (28.4%) had mediastinal hypermetabolic foci on their 18F-FDG PET/CT consistent with sarcoidosis. It identified a biopsy site in two cases, which were consistent with sarcoidosis. At the end of the study, six patients (10%) had a proven sarcoidosis, six patients (9%) were considered as having a presumed sarcoidosis and 18 patients (26.9%) as having indeterminate sarcoidosis. 18F-FDG PET/CT enabled the diagnosis of presumed sarcoidosis in these six patients. An older age at diagnosis (p=0.004) and the presence of synechiae (p=0.02) were significantly related to an abnormal 18F-FDG PET/CT, with a trend for an elevated ACE (p=0.0993). We established a nomogram to estimate the probability of having positive findings on the 18F-FDG PET/CT according to different predictive factors.Conclusion18F-FDG PET/CT enabled the diagnosis of intraocular sarcoidosis even in patients with a normal CT scan. Older age at diagnosis, presence of synechiae and elevated ACE are associated with positive findings on 18F-FDG PET/CT consistent with sarcoidosis.

Download Full-text

Potential and Clinical Significance of 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography for Evaluating Liver Cancer Response to Lenvatinib Treatment

Oncology ◽

10.1159/000510754 ◽

2020 ◽

pp. 1-8

Author(s):

Daiki Yamashige ◽

Yusuke Kawamura ◽

Masahiro Kobayashi ◽

Junichi Shindoh ◽

Yuta Kobayashi ◽

...

Keyword(s):

Computed Tomography ◽

Positron Emission Tomography ◽

Fdg Pet ◽

Emission Tomography ◽

Fluorodeoxyglucose Positron Emission Tomography ◽

Recist 1.1 ◽

Positron Emission ◽

Pet Ct ◽

Fdg Pet Ct ◽

Fluorodeoxyglucose Positron Emission

Background: The sensitivity of 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG-PET/CT) in hepatocellular carcinoma (HCC) is low; however, clinical evidence demonstrating its prognostic value in patients with HCC has recently been reported. This study aimed to assess the value of 18F-FDG-PET/CT as a tool for evaluating the response of HCC to lenvatinib treatment. Methods: We evaluated 11 consecutive patients with HCC diagnosed by dynamic CT or magnetic resonance imaging combined with 18F-FDG-PET/CT from April 2018 to December 2019. The tumor-to-normal liver ratio (TLR) of the target tumor was measured before and during the course of lenvatinib treatment with 18F-FDG-PET/CT (pre and post analysis, respectively), with a TLR ≥2 classified as PET-positive HCC. At the time of each evaluation, we also used the Response Evaluation Criteria in Solid Tumors (RECIST) 1.1, the modified RECIST (mRECIST), and the tumor marker alfa-fetoprotein (AFP). Results: Of 11 patients, 3 (27%) and 8 (73%) had an objective response to lenvatinib treatment at the time of post-analysis by RECIST 1.1 and mRECIST, respectively. There were 3 (27%) and 7 (64%) patients with PET-positive HCC at the time of pre- and post-analysis, respectively. There was a significant correlation between the rates of change in AFP and TLR during lenvatinib treatment (r = 0.69, p = 0.019). Based on these results, we were able to perform liver resection on 4 patients with PET-positive HCC as conversion therapy. Three samples from these patients showed poorly differentiated tumors. Conclusion: 18F-FDG-PET/CT has potential as an evaluation tool for describing biological tumor behavior and reflecting disease progression, location, and treatment response. This modality may provide useful information for considering prognosis and subsequent therapy.

Download Full-text